Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy

Andrew S. Bomback, Yelena Rekhtman, Philip J. Klemmer, Pietro A. Canetta, Jai Radhakrishnan, Gerald B. Appel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Aldosterone levels increase in 30%-40% of patients on angiotensin- converting enzyme inhibitors and/or angiotensin receptor blockers over the long term. This "aldosterone breakthrough" may carry important clinical consequences given aldosterone's nonepithelial, pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren 300 mg daily (A), valsartan 320 mg daily (V), or aliskiren 150 mg + valsartan 160 mg daily (A+V) for 9 months. Eligible subjects had proteinuria >300 mg/day, estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m 2, and systolic blood pressure (BP) >130 or diastolic BP >80 mm Hg. Serum and 24-hour urine aldosterone (indexed to 24-hour urine Na) were checked before initiation of therapy and at 3, 6, and 9 months. Aldosterone breakthrough was defined as a sustained increase from baseline aldosterone by study end. The study was intended to enroll 120 subjects but was terminated early by the sponsor. We present here the results of 33 subjects who completed the protocol, of which 12 were randomized to A, 11 were randomized to V, and 10 were randomized to A+V. Mean baseline eGFR was 75.5 (±23.3) mL/min/1.73 m2; baseline proteinuria was 3104 (±2943) mg/day; and baseline BP was 134.7 (±10.5)/84.8 (±8.4) mm Hg. Three (27%) subjects on V, three (25%) subjects on A, and three (30%) subjects on A+V had aldosterone breakthrough. Mean proteinuria reduction was 31% from baseline in all subjects: 30% in subjects with breakthrough vs. 32% in subjects without breakthrough. Mean BP reduction was 11.0/8.8 mm Hg in all subjects: 8.4/6.1 mm Hg in subjects with breakthrough vs. 12.0/9.8 mm Hg in subjects without breakthrough. Aliskiren, alone or in combination with valsartan, did not reduce the incidence of aldosterone breakthrough in subjects with hypertension and proteinuria compared with conventional RAAS blockade.

Original languageEnglish (US)
Pages (from-to)338-345
Number of pages8
JournalJournal of the American Society of Hypertension
Volume6
Issue number5
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Valsartan
Aldosterone
Blood Pressure
Proteinuria
Renin-Angiotensin System
Therapeutics
Glomerular Filtration Rate
Urine
aliskiren
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Renin

Keywords

  • aldosterone
  • Aldosterone breakthrough
  • proteinuria
  • renin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. / Bomback, Andrew S.; Rekhtman, Yelena; Klemmer, Philip J.; Canetta, Pietro A.; Radhakrishnan, Jai; Appel, Gerald B.

In: Journal of the American Society of Hypertension, Vol. 6, No. 5, 09.2012, p. 338-345.

Research output: Contribution to journalArticle

Bomback, Andrew S. ; Rekhtman, Yelena ; Klemmer, Philip J. ; Canetta, Pietro A. ; Radhakrishnan, Jai ; Appel, Gerald B. / Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. In: Journal of the American Society of Hypertension. 2012 ; Vol. 6, No. 5. pp. 338-345.
@article{1f20efa78423480ab7e718bd1f4db7c1,
title = "Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy",
abstract = "Aldosterone levels increase in 30{\%}-40{\%} of patients on angiotensin- converting enzyme inhibitors and/or angiotensin receptor blockers over the long term. This {"}aldosterone breakthrough{"} may carry important clinical consequences given aldosterone's nonepithelial, pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren 300 mg daily (A), valsartan 320 mg daily (V), or aliskiren 150 mg + valsartan 160 mg daily (A+V) for 9 months. Eligible subjects had proteinuria >300 mg/day, estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m 2, and systolic blood pressure (BP) >130 or diastolic BP >80 mm Hg. Serum and 24-hour urine aldosterone (indexed to 24-hour urine Na) were checked before initiation of therapy and at 3, 6, and 9 months. Aldosterone breakthrough was defined as a sustained increase from baseline aldosterone by study end. The study was intended to enroll 120 subjects but was terminated early by the sponsor. We present here the results of 33 subjects who completed the protocol, of which 12 were randomized to A, 11 were randomized to V, and 10 were randomized to A+V. Mean baseline eGFR was 75.5 (±23.3) mL/min/1.73 m2; baseline proteinuria was 3104 (±2943) mg/day; and baseline BP was 134.7 (±10.5)/84.8 (±8.4) mm Hg. Three (27{\%}) subjects on V, three (25{\%}) subjects on A, and three (30{\%}) subjects on A+V had aldosterone breakthrough. Mean proteinuria reduction was 31{\%} from baseline in all subjects: 30{\%} in subjects with breakthrough vs. 32{\%} in subjects without breakthrough. Mean BP reduction was 11.0/8.8 mm Hg in all subjects: 8.4/6.1 mm Hg in subjects with breakthrough vs. 12.0/9.8 mm Hg in subjects without breakthrough. Aliskiren, alone or in combination with valsartan, did not reduce the incidence of aldosterone breakthrough in subjects with hypertension and proteinuria compared with conventional RAAS blockade.",
keywords = "aldosterone, Aldosterone breakthrough, proteinuria, renin",
author = "Bomback, {Andrew S.} and Yelena Rekhtman and Klemmer, {Philip J.} and Canetta, {Pietro A.} and Jai Radhakrishnan and Appel, {Gerald B.}",
year = "2012",
month = "9",
doi = "10.1016/j.jash.2012.07.003",
language = "English (US)",
volume = "6",
pages = "338--345",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy

AU - Bomback, Andrew S.

AU - Rekhtman, Yelena

AU - Klemmer, Philip J.

AU - Canetta, Pietro A.

AU - Radhakrishnan, Jai

AU - Appel, Gerald B.

PY - 2012/9

Y1 - 2012/9

N2 - Aldosterone levels increase in 30%-40% of patients on angiotensin- converting enzyme inhibitors and/or angiotensin receptor blockers over the long term. This "aldosterone breakthrough" may carry important clinical consequences given aldosterone's nonepithelial, pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren 300 mg daily (A), valsartan 320 mg daily (V), or aliskiren 150 mg + valsartan 160 mg daily (A+V) for 9 months. Eligible subjects had proteinuria >300 mg/day, estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m 2, and systolic blood pressure (BP) >130 or diastolic BP >80 mm Hg. Serum and 24-hour urine aldosterone (indexed to 24-hour urine Na) were checked before initiation of therapy and at 3, 6, and 9 months. Aldosterone breakthrough was defined as a sustained increase from baseline aldosterone by study end. The study was intended to enroll 120 subjects but was terminated early by the sponsor. We present here the results of 33 subjects who completed the protocol, of which 12 were randomized to A, 11 were randomized to V, and 10 were randomized to A+V. Mean baseline eGFR was 75.5 (±23.3) mL/min/1.73 m2; baseline proteinuria was 3104 (±2943) mg/day; and baseline BP was 134.7 (±10.5)/84.8 (±8.4) mm Hg. Three (27%) subjects on V, three (25%) subjects on A, and three (30%) subjects on A+V had aldosterone breakthrough. Mean proteinuria reduction was 31% from baseline in all subjects: 30% in subjects with breakthrough vs. 32% in subjects without breakthrough. Mean BP reduction was 11.0/8.8 mm Hg in all subjects: 8.4/6.1 mm Hg in subjects with breakthrough vs. 12.0/9.8 mm Hg in subjects without breakthrough. Aliskiren, alone or in combination with valsartan, did not reduce the incidence of aldosterone breakthrough in subjects with hypertension and proteinuria compared with conventional RAAS blockade.

AB - Aldosterone levels increase in 30%-40% of patients on angiotensin- converting enzyme inhibitors and/or angiotensin receptor blockers over the long term. This "aldosterone breakthrough" may carry important clinical consequences given aldosterone's nonepithelial, pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren 300 mg daily (A), valsartan 320 mg daily (V), or aliskiren 150 mg + valsartan 160 mg daily (A+V) for 9 months. Eligible subjects had proteinuria >300 mg/day, estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m 2, and systolic blood pressure (BP) >130 or diastolic BP >80 mm Hg. Serum and 24-hour urine aldosterone (indexed to 24-hour urine Na) were checked before initiation of therapy and at 3, 6, and 9 months. Aldosterone breakthrough was defined as a sustained increase from baseline aldosterone by study end. The study was intended to enroll 120 subjects but was terminated early by the sponsor. We present here the results of 33 subjects who completed the protocol, of which 12 were randomized to A, 11 were randomized to V, and 10 were randomized to A+V. Mean baseline eGFR was 75.5 (±23.3) mL/min/1.73 m2; baseline proteinuria was 3104 (±2943) mg/day; and baseline BP was 134.7 (±10.5)/84.8 (±8.4) mm Hg. Three (27%) subjects on V, three (25%) subjects on A, and three (30%) subjects on A+V had aldosterone breakthrough. Mean proteinuria reduction was 31% from baseline in all subjects: 30% in subjects with breakthrough vs. 32% in subjects without breakthrough. Mean BP reduction was 11.0/8.8 mm Hg in all subjects: 8.4/6.1 mm Hg in subjects with breakthrough vs. 12.0/9.8 mm Hg in subjects without breakthrough. Aliskiren, alone or in combination with valsartan, did not reduce the incidence of aldosterone breakthrough in subjects with hypertension and proteinuria compared with conventional RAAS blockade.

KW - aldosterone

KW - Aldosterone breakthrough

KW - proteinuria

KW - renin

UR - http://www.scopus.com/inward/record.url?scp=84866411980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866411980&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2012.07.003

DO - 10.1016/j.jash.2012.07.003

M3 - Article

VL - 6

SP - 338

EP - 345

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 5

ER -